OncoMatch/Clinical Trials/NCT06812104
Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies.
Is NCT06812104 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments for relapsed or refractory aml and other hematologic malignancies.
Treatment: KK2845_1 · KK2845_2 · KK2845_3 · KK2845_4 · KK2845_5 · KK2845_6 · KK2845_7 · KK2845_8 · KK2845_alternative_1 · KK2845_alternative_2 — This is the first in human study of KK2845. This clinical trial consists of Part 1 (Dose Escalation) and Part 2 (Backfill). For patients with relapsed or refractory acute myeloid leukemia (AML) and other Hematologic Malignancies, in Part 1, the tolerability of KK2845 will be evaluated to determine the maximum tolerated dose (MTD). In Part 2, additional data will be collected by administering KK2845 at dose levels for which tolerability has been confirmed.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: allogeneic hematopoietic stem cell transplant
Exception: allowed if ≥6 months since transplant, no active acute gvhd grade 2+ or active chronic gvhd, and ≥4 weeks since donor lymphocyte infusion
Lab requirements
Blood counts
neutrophil count >500/mm3 (may enroll if expected to improve per investigator)
Kidney function
creatinine clearance ≥50 ml/min (cockcroft-gault); if 30–49 ml/min and serum creatinine ≤1.5x uln, enrollment permitted
Liver function
ast/alt within 3.0x upper reference limit; t-bil within 1.5x upper limit of standard
Cardiac function
lvef ≥50% (muga or echo); qtcf <450 msec (males), <480 msec (females)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06812104 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic hematopoietic stem cell transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages